NEWS: Drug Discovery News: Predicting onset of COVID-1

Written By Guest User

BioSymetrics collaborates with Janssen and Sema4 to Predict the Onset of COVID-19

Sep 07, 2020

JEFFREY BOULEY

BioSymetrics, a biomedical artificial intelligence (AI) company that provides clinical insights and helps researchers develop drugs with greater speed and precision, announced recently a collaboration with Sema4, a patient-centered health intelligence company, and Janssen Pharmaceuticals Inc. The collaboration will focus on predicting the onset and severity of COVID-19 among different populations using machine learning.

To read the full article, go here: https://www.drugdiscoverynews.com/predicting-onset-of-covid-19-14664

Guest User
Previous

EVENT: Hub Xchange Event - AI in Drug Discovery
Next

PRESS RELEASE: BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19